Menu Search
Equities

Smith & Nephew PLC

SNN:NYQ

Smith & Nephew PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)25.33
  • Today's Change0.29 / 1.16%
  • Shares traded492.55k
  • 1 Year change-1.36%
  • Beta0.8464
Data delayed at least 15 minutes, as of Nov 22 2024 19:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Smith & Nephew PLC grew revenues 6.40% from 5.22bn to 5.55bn while net income improved 17.94% from 223.00m to 263.00m.
Gross margin69.04%
Net profit margin5.41%
Operating margin8.47%
Return on assets2.99%
Return on equity5.84%
Return on investment3.62%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Smith & Nephew PLC fell by 44.00m. However, the company earned 608.00m from its operations for a Cash Flow Margin of 10.96%. In addition the company used 448.00m on investing activities and also paid 200.00m in financing cash flows.
Cash flow per share2.21
Price/Cash flow per share11.20
Book value per share11.91
Tangible book value per share2.26
More ▼

Balance sheet in USDView more

Smith & Nephew PLC has a Debt to Total Capital ratio of 41.25%, a lower figure than the previous year's 50.31%.
Current ratio2.51
Quick ratio1.11
Total debt/total equity0.7022
Total debt/total capital0.4125
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 18.14%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)65.90%
EPS growth(5 years)-16.83
EPS (TTM) vs
TTM 1 year ago		39.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.